Mitsubishi UFJ Asset Management Co. Ltd. Has $11.49 Million Position in United Therapeutics Co. (NASDAQ:UTHR)

Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in United Therapeutics Co. (NASDAQ:UTHR) by 11.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 32,246 shares of the biotechnology company’s stock after acquiring an additional 3,312 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in United Therapeutics were worth $11,490,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Signaturefd LLC boosted its holdings in United Therapeutics by 4.7% in the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 30 shares during the last quarter. Parallel Advisors LLC lifted its position in shares of United Therapeutics by 2.8% in the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of United Therapeutics by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after buying an additional 33 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock worth $1,761,000 after buying an additional 39 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the subject of a number of recent analyst reports. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $929,678.52. This represents a 79.51 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 72,500 shares of company stock worth $26,134,500. Insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 0.4 %

Shares of UTHR opened at $308.27 on Tuesday. The business’s fifty day moving average is $339.04 and its 200 day moving average is $355.62. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The stock has a market cap of $13.85 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period last year, the firm earned $4.36 earnings per share. On average, analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.